This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SALT LAKE CITY, Sept. 2, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, is scheduled to present an overview of the Company at two upcoming conferences in New York, NY: the Rodman & Renshaw Global Investment Conference, to be held September 12-15, 2010; and the UBS Global Life Sciences Conference, taking place September 20-22, 2010.
Dr. Hobden and Robert Lollini, Chief Financial Officer and Treasurer, will be available to respond to questions immediately following the presentations and to participate in one-on-one meetings with investors attending the conferences.
Event: Rodman & Renshaw Global Investment Conference
Date: Monday, September 13, 2010
Time: 12:05pm ET
Place: The New York Palace Hotel, New York City (Spellman Salon)
The presentation will be webcast live and can be accessed by visiting the investor relations section of Myrexis' website at
www.myrexis.com. The webcast will be archived for 90 days.
Event: UBS Global Life Sciences Conference
Date: Monday, September 20, 2010
Time: 8:00am ET (Breakout: 8:30am ET)
Place: The Grand Hyatt, New York City
About Myrexis, Inc.
Myrexis is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and preclinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomic drug discovery and clinical and commercial development.
For more information, please visit
The Myrexis, Inc. logo is available at
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the scheduled presentation of an overview of the Company at the Rodman & Renshaw Global Investment Conference on September 13, 2010 and the UBS Global Life Sciences Conference on September 20, 2010. These risks and uncertainties include, but are not limited to: the risk that we may be unable to further identify, develop and achieve commercial success for new products and technologies; the risk that we may be unable to discover drugs that are safer and more efficacious than our competitors; the risk that we may be unable to develop and maintain manufacturing capabilities for our products; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we may be unable to protect our proprietary technologies; the risk of patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in our Form 10-K, for the year ended June 30, 2009, which was filed with the Securities and Exchange Commission on September 28, 2009, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis Inc. undertakes no duty to update this information unless required by law.
CONTACT: Myrexis, Inc.
Patrick M. Burke, Ph.D., V.P., Corporate and
The Ruth Group